Answer: This is inconsistent with the data [see (3, 6) for detail].
Question: This study evaluated common variation; what about rare exonic variation in these genes?
Answer: It is implausible, given that most of the original studies explicitly evaluated common variants (6) . We now know that rare exon variants are very difficult to find, and the genes identified to date were not on anyone's guess list (SETD1A and RBM12).
Question: What about epistatic interactions? (restated: the explicit initial candidate gene guesses did not pan out, so double-down on a more exotic mechanism?).
Answer: It is implausible, not parsimonious, unlikely except under fairly weird circumstances (most interactions are detectible under additivity), and inconsistent with empirical data [Extended Data Figure 7 in (4)].
But these objections miss the point. The track record of candidate gene guessers was no different from picking genes at random. Application of the candidate gene approach is predicated on the assumption of reasonably good guessing, and we cannot convincingly reject the null hypothesis (candidate gene guessing is indistinguishable from picking genes at random).
Johnson et al.
(3) add importantly to the literature on this topic, in aggregate and for specific genes, and for schizophrenia as well as other psychiatric disorders. For example, one of the most highly cited articles in psychiatry (.4300 citations) was in Science in 2003 by Caspi et al. (7) , who reported a gene-environment association of HTTLPR (serotonin transporter gene promoter polymorphism) and early stress on risk for major depressive disorder (7) . It seems pretty clear that this study is wrong given lack of replication in a meta-analysis (N = 38,802) (8) and in an exceptionally similar study (9) . Implications? Following on from Johnson et al. (3), if candidate gene guessing does not work, how can we make progress? The strongest and most consistent clue that we have into the etiology of schizophrenia is its marked twin/pedigree heritability. How can we move from this broad clue to specific, reproducible, and actionable hypotheses about the etiology of schizophrenia? We recently put forth an agenda (10) . I suggest the following. First, historical candidate gene studies did not work, and cannot work [following from elementary school math and the now extensive knowledge of the genetic "architecture" of schizophrenia (10); the caveat being there may be a few edge-case exceptions]. There is little evidence to support almost all of the historical candidate genes for schizophrenia (including impact factor heavy hitters such as COMT, BDNF, DISC1, and dysbindin).
The data suggest that candidate gene guessing should be retired. This is not a new statement, as candidate gene studies
SEE CORRESPONDING ARTICLE ON PAGE 702
have been controversial for decades, but the case can now be made forcibly.
In the scrappy, vibrant, and iconoclastic free-for-all that should characterize scientific inquiry, researchers, reviewers, journal editors, and readers can of course do whatever they choose. This includes recommending, funding, publishing, and reading/citing poor-quality candidate gene studies that do not meet the mature and widely accepted quality standards of human complex trait genomics (i.e., professional consideration of sample size, false findings due to poor control of multiple comparisons, power, population stratification). In my opinion, ignoring the body of work that has been amassed about the genetic basis of schizophrenia is wasteful and unscientific. It might yield an article somewhere, but it will not contribute to true progress. (The free-for-all sword cuts both ways, and the genomic Twitterverse delights in refuting shoddy candidate gene guesses hours after appearing online.)
Second, perhaps a reader disagrees deeply with these conclusions, and has some novel candidate gene guess. Most readers who care deeply about schizophrenia genomics are highly pragmatic and would be pleased to be proven incorrect. But, note the emphasis on "proven" and not "opined": if you want your guess to be believed, the burden of proof is appropriately very high and requires meeting the standards now applied in human complex trait genomics. "Suggestive" findings are not enough. Mimicking an approach that yielded a high-profile paper in the early 2000s will not work now.
Third, how do we progress? This requires a longer answer (10) . Briefly, we now know what to do, and we are making real progress. Nature has designed the genetic architectures of basically all common human diseases, disorders, and traits in a complex way. (For the present audience, this includes structural brain imaging phenotypes whose architectures are similar to other complex traits.) Schizophrenia is truly complex, and simple approaches, models, and guesswork have consistently failed. We should use approaches that have yielded evidence-but, we now know that the required sample sizes are huge. Therefore, progress requires collaboration and openscience approaches, and psychiatry is among the leaders in medicine. If you have an idea, test it out using online resources such as Functional Mapping and Annotation of Genome-Wide Association Studies (http://fuma.ctglab.nl); freely available summary statistics (http://www.med.unc.edu/pgc/); or individual-level data obtainable by application to genomic repositories such as the European Genome-Phenome Archive (https://www.ebi.ac.uk/ega), dbGaP (https://www.ncbi.nlm.nih. gov/gap), and NIMH Genomics (https://www.nimhgenetics.org).
Last, if progress requires meta-analysis and consortia (e.g., the next Psychiatric Genomics Consortium schizophrenia article has over 60,000 cases), what is one researcher to do? First, if you have an idea, test it out (see "how do we progress?" above) and, if meritorious, figure out an effective way to collaborate with groups that can put your idea to a stronger test. Second, instead of doing candidate gene genotyping, genotype with a single nucleotide polymorphism array. Single nucleotide polymorphism array prices are historically low (w$45 per subject for 700,000 markers) to get a large amount of useful information. These can be used to identify ancestry and large copy number variants, and generate genetic risk scores that summarize the inherited liability to schizophrenia. These are surely far more useful than genotyping BDNF val/met, COMT val/met, or HTTLPR. As with every technology, and although the methods are standard, there are many ways to make a complete hash of the data, and this not for the unwise, incautious, or inexperienced.
Scientific inquiry should be self-correcting. I strongly suggest that we abandon candidate gene guesswork (as historically applied) as they have only provided false directions and wasted effort. Better approaches are of proven value. Circling back to Feynman (1): "If it disagrees with experiment it is wrong. That is all there is to it."
